IL139220A0 - Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection - Google Patents

Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection

Info

Publication number
IL139220A0
IL139220A0 IL13922099A IL13922099A IL139220A0 IL 139220 A0 IL139220 A0 IL 139220A0 IL 13922099 A IL13922099 A IL 13922099A IL 13922099 A IL13922099 A IL 13922099A IL 139220 A0 IL139220 A0 IL 139220A0
Authority
IL
Israel
Prior art keywords
ribavirin
infection
combination therapy
interferon alpha
chronic hepatitis
Prior art date
Application number
IL13922099A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL139220(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL139220A0 publication Critical patent/IL139220A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL13922099A 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection IL139220A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (1)

Publication Number Publication Date
IL139220A0 true IL139220A0 (en) 2001-11-25

Family

ID=22151354

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13922099A IL139220A0 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
IL139220A IL139220A (en) 1998-05-15 2000-10-23 Use of ribavirin for preparing a pharmaceutical composition for treating in combination with interferon alpha naive patients having chronic hepatitis c infection
IL207259A IL207259A (en) 1998-05-15 2010-07-27 Use of drugs that include, inter alia, ribavirin and interferon alfa for the treatment of chronic hepatitis C patients not previously treated with antiviral therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL139220A IL139220A (en) 1998-05-15 2000-10-23 Use of ribavirin for preparing a pharmaceutical composition for treating in combination with interferon alpha naive patients having chronic hepatitis c infection
IL207259A IL207259A (en) 1998-05-15 2010-07-27 Use of drugs that include, inter alia, ribavirin and interferon alfa for the treatment of chronic hepatitis C patients not previously treated with antiviral therapy

Country Status (22)

Country Link
EP (3) EP2305287A1 (enExample)
JP (2) JP5281726B2 (enExample)
KR (1) KR100694345B1 (enExample)
CN (1) CN1230198C (enExample)
AR (1) AR019551A1 (enExample)
AT (1) ATE216591T1 (enExample)
AU (2) AU766597B2 (enExample)
BR (1) BR9910505A (enExample)
CA (1) CA2331823A1 (enExample)
CZ (1) CZ300540B6 (enExample)
DE (1) DE69901321T2 (enExample)
DK (1) DK0956861T3 (enExample)
ES (1) ES2172288T3 (enExample)
HU (1) HU230432B1 (enExample)
IL (3) IL139220A0 (enExample)
MY (1) MY129244A (enExample)
NO (1) NO330715B1 (enExample)
NZ (1) NZ507621A (enExample)
PT (1) PT956861E (enExample)
SK (1) SK288038B6 (enExample)
TW (1) TWI277424B (enExample)
WO (1) WO1999059621A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AR021876A1 (es) * 1998-12-18 2002-08-07 Schering Corp Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CN1420723A (zh) * 1999-12-23 2003-05-28 Icn药品公司 L－核苷、l－核苷酸及其类似物的组合物和方法
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
EP2275557A1 (en) * 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
CN1516599A (zh) * 2000-10-18 2004-07-28 ���鹫˾ 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
JP2005504087A (ja) 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド ４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
KR20040053291A (ko) * 2001-11-09 2004-06-23 바이오메디신즈 인코포레이티드 오메가 인터페론을 이용한 질환 치료 방법
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
PT1576138T (pt) 2002-11-15 2017-05-03 Idenix Pharmaceuticals Llc 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US20050049204A1 (en) * 2003-03-28 2005-03-03 Otto Michael J. Compounds for the treatment of flaviviridae infections
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
EA008766B1 (ru) * 2003-04-17 2007-08-31 Арес Трейдинг С.А. Интерферон-бета при тяжелом остром респираторном синдроме (sars)
SI2604620T2 (sl) 2003-05-30 2024-10-30 Gilead Pharmasset Llc Modificirani fluorirani nukleozidni analogi
US7482149B2 (en) * 2003-06-09 2009-01-27 Genome Institute Of Singapore Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
BRPI0413474A (pt) * 2003-08-13 2006-10-17 Smith Howard J & Ass Pty Ltd uso de interferon e ribavirina e kit para uso no tratamento de infecções virais
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
TWI437990B (zh) * 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
CN101448497B (zh) 2006-01-09 2013-07-10 罗马克实验室有限公司 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
BRPI0814363A2 (pt) 2007-07-25 2015-01-27 Biolex Therapeutics Inc Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) * 2008-05-22 2009-10-10 Сергей Юрьевич Родионов Способ лечения хронических вирусных гепатитов
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8716012B2 (en) 2009-05-08 2014-05-06 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
CN103179974A (zh) * 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
SMT201800087T1 (it) 2011-09-16 2018-03-08 Gilead Pharmasset Llc Metodi per trattare hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EA029081B9 (ru) 2013-01-31 2018-09-28 Джилид Фармассет Ллс Комбинированный состав двух противовирусных соединений
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
PT730470E (pt) 1993-11-10 2002-08-30 Enzon Inc Conjugados melhorados de interferao-polimero
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
CA2236591C (en) * 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
ATE206618T1 (de) * 1997-09-21 2001-10-15 Schering Corp Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infektion

Also Published As

Publication number Publication date
EP0956861B1 (en) 2002-04-24
IL207259A0 (en) 2010-12-30
HUP0103423A2 (hu) 2002-01-28
IL207259A (en) 2016-08-31
HK1021131A1 (en) 2000-06-02
DK0956861T3 (da) 2002-07-01
CZ300540B6 (cs) 2009-06-10
NZ507621A (en) 2002-11-26
EP1213029A1 (en) 2002-06-12
ATE216591T1 (de) 2002-05-15
AU766597B2 (en) 2003-10-16
JP2011173898A (ja) 2011-09-08
DE69901321D1 (de) 2002-05-29
KR100694345B1 (ko) 2007-03-12
AR019551A1 (es) 2002-02-27
WO1999059621A1 (en) 1999-11-25
HUP0103423A3 (en) 2003-11-28
BR9910505A (pt) 2001-01-02
MY129244A (en) 2007-03-30
SK17102000A3 (sk) 2001-05-10
JP2002515453A (ja) 2002-05-28
NO20005755L (no) 2001-01-12
AU2005220271B2 (en) 2005-11-03
EP0956861A1 (en) 1999-11-17
PT956861E (pt) 2002-08-30
CZ20004177A3 (cs) 2001-04-11
TWI277424B (en) 2007-04-01
IL139220A (en) 2013-02-28
NO330715B1 (no) 2011-06-20
HU230432B1 (hu) 2016-06-28
CA2331823A1 (en) 1999-11-25
EP2305287A1 (en) 2011-04-06
AU2005220271A1 (en) 2005-11-03
CN1230198C (zh) 2005-12-07
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
SK288038B6 (en) 2013-01-02
AU2005220271B8 (en) 2010-11-18
ES2172288T3 (es) 2002-09-16
DE69901321T2 (de) 2002-12-12
JP5281726B2 (ja) 2013-09-04
NO20005755D0 (no) 2000-11-14
KR20010043624A (ko) 2001-05-25
AU3860099A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
IL139220A0 (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
IL134428A0 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
HU228218B1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
EP0818976A4 (en) DISPOSABLE MASK AND SUCTION CATHETER
ID24910A (id) Karboksilat nukleosid hemisulfat dan penggunaan dalam perlakuan infeksi viral
PL311031A1 (en) Use of concentrates comprising vwf in complex therapy in case of treatment by using anticoagulants and fibrinolitic drugs
ZA898234B (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
EP1224939A4 (en) INTERFERON-BASED COMPLEX AND ITS USE IN MEDICINE
AU3857389A (en) Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
HUP0200731A3 (en) Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies
EP1908477A3 (en) Combination of temozolomide and pegylated interferon-alpha for treating cancer
GB9725480D0 (en) Cytokines and their use in the treatment of established chronic infections and cancers
HK1035906A (en) Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
AU8086498A (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiencyvirus infection